Nasonex sinus

Nasonex Sinus is a metered dose nasal spray for local use in the treatment of diseases of the nasal cavity. It is a corticosteroid with decongestant properties.

[ 1 ], [ 2 ]

Indications Nasonex sinus

Among the indications:

• year-round/seasonal allergic rhinitis in children aged 2+ and adults. As a preventative measure for severe or moderate allergic rhinitis, the spray should be started approximately 1 month before the expected onset of allergens;
• for acute sinusitis (children 12+ years old, as well as adults) as an additional medicinal tool;
• the appearance of signs of acute sinusitis, without symptoms of the development of a severe form of bacterial infection (children 12+ years old, as well as adults);
• nasal polyps, as well as the symptoms they cause, such as loss of smell or nasal congestion (can only be used for people over 18 years of age).

Release form

Available as a suspension in 10 g bottles (enough for 60 doses). Additionally included is a capped spray nozzle. The package contains 1 bottle.

[ 3 ]

Pharmacodynamics

Mometasone furoate is a synthetic corticosteroid used topically. It has potent anti-inflammatory properties.

The presence of anti-inflammatory and anti-allergic properties in the drug is due to the ability of the active substance to inhibit the process of secretion of conductors of the allergic response. The active component significantly reduces the rate of synthesis and release of leukotrienes found in the leukocytes of patients with allergic diseases.

Mometasone furoate has a much higher (10 times) activity in suppressing the processes of release and synthesis of IL-1 and IL-5, as well as IL-6 with TNFα, than other steroids (this group includes betamethasone with beclomethasone dipropionate, and also dexamethasone with hydrocortisone). In addition, this substance significantly slows down the production of Th2 type cytokines, as well as IL-4 with IL-5, occurring in human CD4+ T-lymphocytes. The active substance slows down the production of IL-5 6 times faster (than betamethasone and beclomethasone dipropionate).

[ 4 ], [ 5 ]

Pharmacokinetics

The bioavailability of the active component in blood plasma after intranasal administration is <1%. The suspension is poorly absorbed from the gastrointestinal tract, and the small amount that can be swallowed undergoes primary active metabolism after absorption. Excretion occurs with bile, mainly in the form of decay products. A small amount of the substance is excreted with urine.

Dosing and administration

To eliminate the symptoms of seasonal/year-round allergic rhinitis in children aged 12 and over and adults, the following dosage is required (both therapeutic and prophylactic) - 2 sprays (1 spray - 50 mcg) in each nostril once a day (a total of 200 mcg of medicine per day). Upon achieving the required therapeutic result, you should switch to maintenance treatment - reduce the dose to 1 spray in each nostril once a day (a total of 100 mcg of medicine per day).

In cases where the severity of the disease manifestations does not decrease, it is allowed to increase the daily dosage to the maximum: 4 sprays in each nostril once a day (total daily dose is 400 mcg of the medicine). Once the desired effect is achieved, the dosage should be reduced.

Children aged 2-11 years should be prescribed a dosage equal to 1 spray (50 mcg) in each nostril once a day (a total of 100 mcg of medicine per day).

As an auxiliary tool in the treatment of acute sinusitis, adults and children over 12 years of age should be prescribed the medicine in a dosage of 2 sprays (50 mcg) in each nostril twice a day (in general, the daily dosage in this case is 400 mcg).

In cases where it is not possible to reduce the severity of the symptoms of the disease using the recommended therapeutic dosage, it is allowed to increase it to 4 sprays on each nostril twice a day (thus, 800 mcg of the medicine is obtained per day). Once the desired result is achieved, the dosage should be reduced.

Acute rhinosinusitis - for children aged 12 years and over, and for adults the dosage is 2 sprays (50 mcg) in each nostril twice a day (400 mcg of medicine per day).

Removal of nasal polyps - patients aged 18 years and over are prescribed 2 sprays (50 mcg) in each nostril twice a day (in total, 400 mcg per day). Upon achieving the desired result, it is necessary to reduce the dosage of the spray to 2 sprays in each nostril once a day (in total, 200 mcg of the medicine per day).

Use Nasonex sinus during pregnancy

The drug's effects on pregnant women have not been tested, but since Nasonex sinus is a glucocorticosteroid, it should be prescribed during this period only in cases of acute need, when the benefit to the mother is higher than the possible risk of developing negative consequences for the fetus.

In newborns whose mothers used this GCS during pregnancy, the function of the adrenal glands must be carefully checked to prevent the development of their hypofunction.

Contraindications

Among the contraindications:

• individual intolerance to the active component or other substances included in the drug;
• the presence of an untreated local infectious process in the patient, in which the nasal mucosa is also involved;
• Because GCS have properties that allow them to suppress the process of wound regeneration, patients who have recently undergone surgery in the nasal area (or have recently received injuries) are prohibited from using this drug until the damaged area has healed.

[ 6 ], [ 7 ]

Side effects Nasonex sinus

During clinical testing of the drug in the process of eliminating seasonal/year-round rhinitis of allergic origin, the following side effects were identified:

• in 8% of cases – headaches or nosebleeds (pronounced bleeding or the release of blood clots or mucus);
• in 4% of cases – development of pharyngitis;
• in 2% of cases – irritation or severe burning in the nose;
• In 1% of cases, an ulcerative process developed on the nasal mucosa.

As a result of intranasal administration of the active component of the drug, in some cases a rapidly developing allergic reaction is possible (for example, the appearance of dyspnea or bronchospasm). Isolated reactions of Quincke's edema or anaphylaxis developed, as well as disorders of smell and taste.

Interactions with other drugs

In the case of combining the drug with Loratadine, no noticeable effect on the latter's levels (as well as its main breakdown product) in blood plasma was detected. The active substance of Nasonex sinus (mometasone furoate) was not detected in blood plasma even at a minimal level.

[ 8 ], [ 9 ]

Storage conditions

The spray should be stored in standard conditions for medications, at a temperature of no more than 25 ^o C. The medicine must not be frozen.

Shelf life

Nasonex sinus is permitted to be used for 3 years from the date of manufacture of the medicine.